Complement inhibitory therapeutics and xenotransplantation.
Once complement-mediated HAR has been inhibited, the full spectrum of cellular and antibody-mediated inflammatory and immune responses characteristic of acute and chronic rejection will need to be counter-manded. But the fact remains that if xenotransplantation is to become a clinical reality, a clinically relevant means of inhibiting complement activation will be required. Soluble complement receptor type 1 provides such a therapeutic option and an option where the dosing regimen is under the control of the physician and can be adjusted in response to the needs of the patient.
Ryan
U S
US
T Cell Sciences, Inc., Needham, Massachusetts 02194, USA.
D000818:Animals; D003167:Complement Activation; D050577:Complement C3-C5 Convertases / Q000037:antagonists & inhibitors; D003169:Complement Inactivator Proteins / Q000627:therapeutic use*; D015938:Complement Membrane Attack Complex / Q000378:metabolism; D004730:Endothelium, Vascular / Q000502:physiology; D006082:Graft Enhancement, Immunologic / Q000379:methods*; D006084:Graft Rejection / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology; D006801:Humans; D008252:Macaca fascicularis; D011951:Receptors, Complement / Q000502:physiology; D013045:Species Specificity; D013552:Swine; D014183:Transplantation, Heterologous / Q000276:immunology*; D016042:Transplantation, Heterotopic
D003169:Complement Inactivator Proteins; D015938:Complement Membrane Attack Complex; D011951:Receptors, Complement; D050577:Complement C3-C5 Convertases